Skip to main content

This job has expired

You will need to login before you can apply for a job.

Principal Engineer, Cell Therapy Process Development

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Dec 4, 2021

Job Details

Why Join Intellia? 

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. 

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done. 

We want all of our people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.   

How you will Achieve More with Intellia:

You will join the growing Tech Ops team as a leader in the cell therapy process development function, responsible for the development and scale up of robust manufacturing processes. In this critical role, your team will collaborate effortlessly with colleagues in the Cell Therapy PD team to develop and characterize processes for Intellia’s ex vivo pipeline within defined timelines. Your team will be responsible for execution of our full-scale manufacturing process production activities supporting PD and other functions. Other responsibilities include:

  • Independently drive and execute process development and scale up activities to ensure robustness and scalability of autologous and allogeneic cell therapy processes for successful tech transfer to CDMOs

  • Perform reproducible development runs and generate high quality drug product material to support other functions, i.e., preclinical studies and analytical development

  • Be a strong leader in tech transfer of our processes to CDMOs, including training, troubleshooting, and protocol and batch record review

  • Partner with CDMOs and other internal and external partners, working collaboratively and bringing a strong technical presence to ensure our programs’ success

  • Contribute to documentation requirements, including reports and regulatory documents to support future regulatory filings

  • Build and maintain a high performing team of process development engineers, including mentorship and technical oversight

About You:

You are a driven process engineer with experience in cell therapies, including engineered T cell therapies. You are knowledgeable about manufacturing autologous and allogeneic cell processes, including standard cell therapy manufacturing equipment and unit operations. You have demonstrable experience in the development of robust, reliable processes for complex cellular products. You are willing to be a strong voice with CDMOs to effectively transfer processes and resolve problems. You are collaborative by nature and comfortable in a fast-paced environment with competing priorities. Other qualifications include:

  • Degree in chemical or biological engineering or related field

  • Demonstrable experience in scale up and process engineering of cell therapies within closed systems

  • Sound understanding of cell therapies, ideally engineered T cell therapies, as evidenced by 8+ years hands on experience in cell therapy process development of an autologous or allogeneic product

  • Experience with operation and optimization of cell therapy unit operations, including CliniMACS, LOVO, Sepax, Xuri, etc.

  • Skilled in characterization and analytics of cell therapy products, including cell counts and flow cytometry

  • Previous experience in tech transfer, including CDMO interactions

  • 2+ years management experience preferred, including mentorship, hiring, performance management and career development

Meet your future team:

You will join a high performing, collaborative, and enthusiastic Cell Therapy Process Development team within the Tech Ops organization that supports Intellia’s ex vivo pipeline. The team is a rapidly growing group of engineers and scientists who work seamlessly together to develop robust processes for our cell therapy programs. In our team, we encourage asking questions, taking risks, and we look forward to nurturing your professional growth and development.

This is a key role that will interface with stakeholders in our CDMOs and internal teams, including external manufacturing and supply chain, analytical development, and other process development functions, as well as the Cell Therapy Process Development team. You will build a new small group within the larger team to support our ex vivo process engineering and scale up efforts. You will report directly to the Director, Cell Therapy Process Development, who is excited to help grow and develop team members so that everyone can reach their long-term career goals.

Covid-19 Vaccination Policy: Effective Monday, January 3, 2022, all Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert